MGI Tech's conservative balance sheet could likely eliminate its debt easily. However, future earnings will determine its ability to maintain a healthy balance sheet. The company's revenue shrinkage and pre-interest, pre-tax loss last year is worrisome. The company may need to raise capital again soon.
MGI Tech's P/S ratio may be overvalued amid poor revenue performance and average future growth estimates. Investors might be overpaying with no clear justification, risking long-term share price sustainability.
MGI Tech Co., Ltd. Stock Forum
Last Friday, WuXi AppTec's shares tumble by 20% in Hong Kong and fall by a 10% limit-down in mainland China.
Other CRO stocks including Medicilon are also falling.
$WUXI BIO (02269.HK)$ $WUXI APPTEC (02359.HK)$ $BGI Genomics (300676.SZ)$ $MGI Tech Co., Ltd. (688114.SH)$ $Shanghai Medicilon Inc. (688202.SH)$ $Novo-Nordisk A/S (NVO.US)$ $Hang Seng H-Share Index ETF (02828.HK)$
No comment yet